Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2024 September Clinical trials Asciminib demonstrates superior efficacy versus tyrosine kinase inhibitors in newly diagnosed ... Read more
2024 April Pharma News New reimbursement in Belgium within the domain of haematology: glofitamab (Columvi®▼) for R... Read more
2023 December Clinical practice Upcoming scientific event: “bringing immunoscience to the clinic” Read more
2023 November Clinical practice The Myeloma platform for online education on multiple myeloma Read more
2023 May Pharma News Vyxeos liposomal now reimbursed in Belgium for patients with untreated high-risk AML Read more
Top
